知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

99 条记录 (耗时 0.022 秒)

    Novel inotropic prodrugs
    1.
    发明授权
    Novel inotropic prodrugs 失效
    新型肌力前药

    公开(公告)号：US4340603A

    公开(公告)日：1982-07-20

    申请号：US177824

    申请日：1980-08-13

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    IPC分类号： A61K31/265 ,  C07C69/74 ,  C07C69/76 ,  C09F5/08

    CPC分类号： C07C211/27 ,  C07C229/24 ,  C07C327/30

    摘要： Novel, transient inotropic prodrug forms of the N-(2-phenylethyl)-.omega.-phenylalkylamines, notably of dobutamine, have (i) the structural formula (I): ##STR1## with the proviso that at least one R.sup.1, R.sup.2 or OR.sup.1, when R.sup.7 and/or R.sup.10 is OR.sup.1, must be R.sup.3 COXCH(R.sup.4)-- or R.sup.3 COXCH(R.sup.4)O--, respectively.

    摘要翻译： 新颖的N-（2-苯基乙基） - ω-苯基烷基胺，特别是多巴酚丁胺的瞬时变性前体药物形式具有（i）结构式（I）：条件是至少一个R 1， R2或OR1，当R7和/或R10为OR1时，必须分别为R3COXCH（R4） - 或R3COXCH（R4）O-。

    Novel dopa/dopamine prodrugs
    2.
    发明授权
    Novel dopa/dopamine prodrugs 失效

    公开(公告)号：US4311706A

    公开(公告)日：1982-01-19

    申请号：US114205

    申请日：1980-01-22

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    IPC分类号： A61K31/165 ,  A61K31/22 ,  A61K31/235 ,  A61K31/245 ,  A61K31/25 ,  A61K31/26 ,  A61K31/265 ,  C07C67/02 ,  C07C69/00 ,  C07C69/74 ,  C07C69/76 ,  C09F5/08 ,  C07C79/46 ,  C07C97/16 ,  C07C101/20 ,  C07C101/44 ,  C07C101/72 ,  C07C102/00 ,  C07C103/20 ,  C07C153/00

    CPC分类号： C07C233/18 ,  C07C217/60 ,  C07C229/36 ,  C07C327/28 ,  Y02P20/55

    摘要： Novel, transient prodrug forms of dopa and dopamine have (i) the structural formula (I): ##STR1## wherein each R is independently selected from the group consisting of hydrogen, R.sup.3 -CO- and ##STR2## wherein X is O, S or NR.sup.6 ; R.sup.1 is hydrogen or --COOR.sup.8 ; R.sup.2 is hydrogen or OR; R.sup.3 is selected from the group consisting of straight or branched chain alkyl having from 1 to 20 carbon atoms; aryl having from 6 to 10 carbon atoms; cycloalkyl having from 3 to 8 carbon atoms; alkenyl having from 2 to 20 carbon atoms; cycloalkenyl having from 4 to 8 carbon atoms; alkynyl having from 2 to 20 carbon atoms; aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, loweracyloxyalkyl, and carboxyalkyl, wherein alkyl, aryl, alkenyl and alkynyl are as defined above; saturated or unsaturated monoheterocyclic or polyheterocyclic, or fused heterocyclic, containing from 1 to 3 of any one or more of the hetero atom N, S or O in each heterocyclic ring thereof and each such ring being from 3- to 8-membered; and mono- or poly-substituted derivatives of the above, each of said substituents being selected from the group consisting of lower alkyl, lower alkoxy, lower acyl, lower acyloxy, halo, haloloweralkyl, cyano, lower alkoxycarbonyl, loweralkylthio, amino, nitro, loweralkylamino, diloweralkylamino, carboxyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl and ##STR3## wherein R.sup.5 is hydrogen or alkyl having from 1 to 10 carbons; R.sup.4 is hydrogen, R.sup.3, lower acyl, cyano, haloloweralkyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl, --CH.sub.2 ONO.sub.2 and --CH.sub.2 OCOR.sup.3 ; R.sup.6 is hydrogen or lower alkyl; R.sup.7 is hydrogen, lower alkyl, COCF.sub.3, COOC(CH.sub.3).sub.3, COOCH.sub.2 C.sub.6 H.sub.5, or other N-protective group conventional to amino acid acid chemistry; R.sup.8 is hydrogen, benzyl, or other conventional, cleavable carboxyl protective group; with the proviso that at least one R must be R.sup.3 COXCH(R.sup.4)--; (ii) the structural formula (I) wherein at least one R.sup.3 CO- moiety comprising at least one R group is the residue of any naturally occurring protein amino acid, the residue of any N-substituted naturally occurring amino acid, which N-substituent is lower alkyl or any amino acid protective group cleavable via hydrogenolysis or hydrolysis, or the residue of an N,N-lower dialkyl or C.sub.4 -C.sub.7 cycloalkylamino acid; and (ii) the non-toxic, pharmaceutically acceptable salts thereof.

    Novel sypathomimetic amine prodrugs
    3.
    发明授权
    Novel sypathomimetic amine prodrugs 失效

    公开(公告)号：US4313956A

    公开(公告)日：1982-02-02

    申请号：US108055

    申请日：1979-12-28

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan ,  Stefano A. Pogany

    IPC分类号： C07C233/16 ,  C07C149/40 ,  A61K31/165 ,  A61K31/22 ,  A61K31/235 ,  A61K31/245 ,  A61K31/25 ,  A61K31/265 ,  C07C67/02 ,  C07C69/00 ,  C07C69/74 ,  C07C69/76 ,  C07C79/46 ,  C07C97/16 ,  C07C101/20 ,  C07C101/44 ,  C07C101/72 ,  C07C102/00 ,  C07C103/20 ,  C07C153/00 ,  C09F5/08

    CPC分类号： C07C233/16 ,  Y02P20/55

    摘要： Novel, transient prodrug forms of the phenolic dihydroxy sympathomimetic amines have (i) the structural formula (I): ##STR1## wherein X is O, S or NR.sup.5 ; n is 1 or 2; R.sup.1 is the monodehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine when n is 1, and the didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine when n is 2; R.sup.2 is selected from the group consisting of straight or branched chain alkyl having from 1 to 20 carbon atoms; aryl having from 6 to 10 carbon atoms; cycloalkyl having from 3 to 8 carbon atoms; alkenyl having from 2 to 20 carbon atoms; cycloalkenyl having from 4 to 8 carbon atoms; alkynyl having from 2 to 20 carbon atoms; aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, loweracyloxyalkyl, and carboxyalkyl, wherein alkyl, aryl, alkenyl and alkynyl are as defined above; saturated or unsaturated monoheterocyclic or polyheterocyclic, or fused heterocyclic, containing from 1 to 3 of any one or more of the hetero atoms N, S or O in each heterocyclic ring thereof and each such ring being from 3- to 8-membered; and mono-or poly-substituted derivatives of the above, each of said substituents being selected from the group consisting of lower alkyl, lower alkoxy, lower acyl, lower acyloxy, halo, haloloweralkyl, cyano, carbethoxy, loweralkylthio, amino, nitro, loweralkylamino, diloweralkylamino, carboxyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl and ##STR2## wherein R.sup.4 is hydrogen or alkyl having from 1 to 10 carbons; R.sup.3 is hydrogen, R.sup.2, lower acyl, cyano, haloloweralkyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl, --CH.sub.2 ONO.sub.2 and --CH.sub.2 OCOR.sup.2 ; R.sup.5 is hydrogen or lower alkyl; (ii) the structural formula (II): ##STR3## wherein X, R.sup.2 and R.sup.3 are as defined above and R.sup.1 is the didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine; (iii) either of the structural formulae (I) or (II) wherein ##STR4## is the residue of any naturally occurring protein amino acid, the residue of any N-substituted naturally occurring amino acid, which N-substituent is lower alkyl or any amino acid protective group cleavable via hydrogenolysis or hydrolysis, or the residue of an N, N-lower dialkyl or C.sub.4 -C.sub.7 cycloalkylamino acid; and (iv) the non-toxic, pharmaceutically acceptable salts thereof.

    Prodrugs for the improved delivery of halogen-containing glucocorticosteroids
    8.
    发明授权
    Prodrugs for the improved delivery of halogen-containing glucocorticosteroids 失效
    用于改善输送含卤素糖皮质激素的前药

    公开(公告)号：US4279900A

    公开(公告)日：1981-07-21

    申请号：US61177

    申请日：1979-07-27

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan

    IPC分类号： C07J33/00 ,  C07J71/00

    CPC分类号： C07J33/005 ,  C07J71/0031 ,  Y10S514/887

    摘要： Novel 3,2'-spiro(1',3'-thiazolidine) compounds which are transient prodrug forms of known 6- and/or 9-haloglucocorticosteroids are described. The subject prodrugs provide improved delivery of the prior art steroids for therapeutic purposes, particularly in alleviating inflammation, and can be prepared by known methods, for example, by reacting the corresponding 3-keto steroids with a thiazolidine forming reagent such as an L-cysteine alkyl ester.

    摘要翻译： 描述了已知的6-和/或9-卤素糖皮质激素的瞬时前药形式的新型3,2'-螺（1'，3'-噻唑烷）化合物。 本发明的前药提供了用于治疗目的的现有技术类固醇的改进递送，特别是在减轻炎症中，并且可以通过已知方法制备，例如通过使相应的3-酮类固醇与形成噻唑烷的试剂例如L-半胱氨酸 烷基酯。

    Novel transient pro-drug forms of phenylbutazone and oxyphenbutazone in compositions and methods of use
    9.
    发明授权
    Novel transient pro-drug forms of phenylbutazone and oxyphenbutazone in compositions and methods of use 失效

    公开(公告)号：US4169147A

    公开(公告)日：1979-09-25

    申请号：US840291

    申请日：1977-10-07

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan

    IPC分类号： C07D231/34 ,  A61K31/44 ,  A61K31/415 ,  A61K31/455

    CPC分类号： C07D231/34 ,  Y02P20/55 ,  Y10S514/87

    摘要： There is provided, novel, transient, pro-drug forms of phenylbutazone and oxyphenbutazone having the following formula: ##STR1## wherein R represents a member selected from the group consisting of a C.sub.1 -C.sub.2 O-alkylsulfonyl group, an aryl(phenyl, p-tolyl, naphthyl)sulfonyl group, a nicotinoyl group, an iso-nicotinoyl group, a picolinoyl group, an N-protected naturally occurring amino acid residue, wherein the protective group on the amino group of the amino acid residue is removable via hydrogenolysis or hydrolysis, and an amino acid residue containing a C.sub.1 -C.sub.2 N,N-dialkylamino or a C.sub.4 -C.sub.6 cycloalkylamino group. ##STR2## wherein X and Y each represent a member selected from the group consisting of a hydrogen atom and a --OR.sub.1 group, with the proviso that either X or Y is a hydrogen atom and that R.sub.2 is a member selected from the same or different groups represented by R.sub.1 ; and wherein R.sub.1 represents a member selected from the group consisting of a hydrogen atom, a C.sub.1 -C.sub.2 O-alkylsulfonyl group, an aryl(phenyl, p-tolyl, naphthyl)sulfonyl group, a --CH.sub.2 COOM group, wherein M represents an alkali or alkaline earth metal (Na, K, Ca, Mg), a --CO-R.sub.3 group, wherein R.sub.3 represents a member selected from the group consisting of a straight or branched C.sub.1 -C.sub.5 alkyl group, a C.sub.1 -C.sub.2 alkoxy group, a phenyl group, a substituted phenyl group, whose substituents are selected from the group consisting of a 2,3, or 4-hydroxy group, a 2,3, or 4-acetyloxy group, and a 2,3, or 4-acetylamino group, a 2,3, or 4-pyridyl group, a 1,2, or 5-imidazolyl group, a residue of an N-protected naturally occurring amino acid, wherein the protective group on the amino group of the amino acid is removable via hydrogenolysis or hydrolysis, and an amino acid residue containing a C.sub.1 -C.sub.2 N, N-dialkylamino or C.sub.4 -C.sub.5 cycloalkylamino group. ##STR3## wherein X or Y represents a member selected from the group consisting of a hydrogen atom and a -OR.sub.1 group, wherein R.sub.1 is as defined above with the proviso that either X or Y is a hydrogen atom, wherein R.sub.4 represents a member selected from the group consisting of a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, an aryl group (phenyl, styryl), a 2,3, or 4-methoxyphenyl group, and a -CH.dbd.CH.sub.2 group; and wherein R.sub.5 represents a member selected from the group consisting of a --OOC- R.sub.6 group, a ##STR4## group, and a -COOM group, wherein M represents an alkali or alkaline earth metal (Na, K, Ca, Mg), wherein R.sub.6 represents a member selected from the group consisting of R.sub.4 as defined above, with the proviso that R.sub.6 cannot be a hydrogen atom, and wherein R.sub.7 and R.sub.8 each represent a C.sub.1 -C.sub.3 alkyl group.The above-identified compounds exhibit anti-inflammatory activity in warm-blooded animals. Upon administration to warm-blooded animals, these compounds pass through the gastrointestinal tract and "cleave" in the bloodstream, thus releasing phenylbutazone or oxyphenbutazone in an anti-inflammatory effective amount at their therapeutic site or sites of activity.

    Prodrugs for improved bioavailability of certain .DELTA..sup.4 -3-ketosteroidal sex hormones
    10.
    发明授权
    Prodrugs for improved bioavailability of certain .DELTA..sup.4 -3-ketosteroidal sex hormones 失效
    用于改善某些DELTA 4-3-酮甾体性激素的生物利用度的前药

    公开(公告)号：US4268441A

    公开(公告)日：1981-05-19

    申请号：US57324

    申请日：1979-07-13

    申请人： Nicholas S. Bodor ,  Kenneth B. Sloan

    发明人： Nicholas S. Bodor ,  Kenneth B. Sloan

    IPC分类号： C07J31/00 ,  C07J33/00 ,  A61K31/58

    CPC分类号： C07J31/006 ,  C07J33/005

    摘要： Transient, orally active thiazolidine type prodrug forms of conventional, natural and synthetic ketosteroidal sex hormones, e.g., of progesterone, testosterone, and the like, are disclosed. The subject compounds can be prepared by known methods, for example, by reacting the corresponding 3-keto or 3,20-diketo steroids with a thiazolidine-forming reagent such as an L-cysteine alkyl ester.

    摘要翻译： 公开了常规的，天然的和合成的酮甾体性激素例如孕酮，睾丸激素等的瞬时口服活性噻唑烷型前药形式。 本发明化合物可以通过已知方法制备，例如通过使相应的3-酮基或3,20-二酮类固醇与形成噻唑烷的试剂如L-半胱氨酸烷基酯反应。